HUT73185A - A novel osteoblastic proliferative factor - Google Patents

A novel osteoblastic proliferative factor

Info

Publication number
HUT73185A
HUT73185A HU9502202A HU9502202A HUT73185A HU T73185 A HUT73185 A HU T73185A HU 9502202 A HU9502202 A HU 9502202A HU 9502202 A HU9502202 A HU 9502202A HU T73185 A HUT73185 A HU T73185A
Authority
HU
Hungary
Prior art keywords
novel
proliferative factor
osteoblastic
bone
diseaese
Prior art date
Application number
HU9502202A
Other languages
Hungarian (hu)
Other versions
HU217082B (en
HU9502202D0 (en
Inventor
Akira Kudo
Tohru Nakanishi
Masaharu Takigawa
Original Assignee
Hoechst Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan filed Critical Hoechst Japan
Publication of HU9502202D0 publication Critical patent/HU9502202D0/en
Publication of HUT73185A publication Critical patent/HUT73185A/en
Publication of HU217082B publication Critical patent/HU217082B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/185Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

This invention relates to a composition for metabolic bone diseaese and/or bone fractures which comprises a pharmaceutically acceptable carrier and human neurotrophin-3 (NT-3). This invention also relates to a method for the treatment and/or prevention of metabolic bone diseaese or bone fractures which comprises administering to a patient in need of said treatment and/or prevention a medicament containing an effective amount of human neurotrophin-3 (NT-3). <IMAGE>
HU9502202A 1994-07-22 1995-07-21 Use of human neurotrophin-3 in the manufacture of a medicament for the treatment of metabolic bone diseases HU217082B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20125794A JP3738281B2 (en) 1994-07-22 1994-07-22 Novel osteoblast growth factor

Publications (3)

Publication Number Publication Date
HU9502202D0 HU9502202D0 (en) 1995-09-28
HUT73185A true HUT73185A (en) 1996-06-28
HU217082B HU217082B (en) 1999-11-29

Family

ID=16437950

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9502202A HU217082B (en) 1994-07-22 1995-07-21 Use of human neurotrophin-3 in the manufacture of a medicament for the treatment of metabolic bone diseases

Country Status (14)

Country Link
US (1) US6080720A (en)
EP (1) EP0704219B1 (en)
JP (1) JP3738281B2 (en)
KR (1) KR100361717B1 (en)
AT (1) ATE206930T1 (en)
AU (1) AU693567B2 (en)
CA (1) CA2154403A1 (en)
DE (1) DE69523250T2 (en)
DK (1) DK0704219T3 (en)
ES (1) ES2161809T3 (en)
FI (1) FI953514A7 (en)
HU (1) HU217082B (en)
NO (1) NO952912L (en)
PT (1) PT704219E (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2523672B1 (en) * 2010-01-15 2016-07-13 Rutgers, the State University of New Jersey Use of vanadium compounds to accelerate bone healing
CN103781358A (en) 2010-12-10 2014-05-07 新泽西医科和牙科大学 Implantable devices coated with insulin mimetic agent composites and methods thereof
US20140322292A1 (en) 2010-12-10 2014-10-30 Rutgers, The State University Of New Jersey Insulin-mimetics as therapeutic adjuncts for bone regeneration
US9931348B2 (en) 2011-07-06 2018-04-03 Rutgers, The State University Of New Jersey Vanadium compounds as therapeutic adjuncts for cartilage injury and repair

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
AU2460595A (en) * 1994-05-06 1995-11-29 Regeneron Pharmaceuticals, Inc. Methods based on the role of neurotrophin 3 in female reproduction

Also Published As

Publication number Publication date
EP0704219A3 (en) 1997-12-10
NO952912L (en) 1996-01-23
DE69523250T2 (en) 2002-07-04
HU217082B (en) 1999-11-29
PT704219E (en) 2002-03-28
CA2154403A1 (en) 1996-01-23
FI953514L (en) 1996-01-23
ATE206930T1 (en) 2001-11-15
US6080720A (en) 2000-06-27
ES2161809T3 (en) 2001-12-16
EP0704219B1 (en) 2001-10-17
FI953514A0 (en) 1995-07-20
EP0704219A2 (en) 1996-04-03
AU2710595A (en) 1996-02-01
DK0704219T3 (en) 2002-02-04
DE69523250D1 (en) 2001-11-22
AU693567B2 (en) 1998-07-02
JP3738281B2 (en) 2006-01-25
KR960003741A (en) 1996-02-23
HU9502202D0 (en) 1995-09-28
NO952912D0 (en) 1995-07-21
JPH0834744A (en) 1996-02-06
KR100361717B1 (en) 2003-07-07
FI953514A7 (en) 1996-01-23

Similar Documents

Publication Publication Date Title
UA29505C2 (en) Pharmaceutical composition for treatment and/or prophylaxis of bone resorption and method of medical treatment and/or prophylaxis of bone resorption in mammals
DE69825292D1 (en) USE OF INOSINE FOR PRODUCING A MEDICINE FOR STIMULATING AXON GROWTH OF CNS NEURONES
RU94027680A (en) Parathyroid hormone and raloxifen for bone mass increase, pharmaceutical composition and method of osseous mass increase
IL114683A0 (en) Combination treatment for inhibiting bone loss
PL319830A1 (en) Treatment of sclerosis multiplex (sm) an dother demyelination states
PL299814A1 (en) Pharmaceutical preparation inhibiting depletion of human bone tissue
IL100069A0 (en) Laser radiation method and device for the treatment of body and dental tissues and bone
NZ266475A (en) Use of recombinant adenovirus of animal origin in making pharmaceutical composition
HUP9802319A3 (en) Pharmaceutical compositions for treatment of bone deficit conditions
IL119774A0 (en) Collimator for reducing patient X-ray dose
ES2173111T3 (en) USE OF FENSERINE FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF COGNOSCITIVE DISORDERS.
ES2160643T3 (en) COMPOSITIONS CONTAINING G-CSF AND PROTEIN OF UNION TO TNF.
GR3032041T3 (en) Idebenone compositions for treating Alzheimer&#39;s disease.
GR3023596T3 (en) Neural implant system
FI962685A7 (en) Use of 2,3-diaryl-1-benzopyran derivatives for the preparation of a medicament for the treatment and prevention of bone loss and osteoporosis
HU9502202D0 (en) A novel osteoblastic proliferative factor
EP0744176A3 (en) Methods for inhibiting bone loss
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
EP0862442A4 (en) Methods for diagnosis and treatment of bloom&#39;s syndrome
CA2287903A1 (en) Method for treating medical conditions using a microprocessor-based video game
AU5699690A (en) Laser apparatus for treating bone and tooth tissue
IL103499A0 (en) Pharmaceutical compositions for treating anxiety in benzodiazepine withdrawn patients
SG64899A1 (en) Method and composition for treatment of patients having decompsated liver disease
IT1276706B1 (en) Bicarbonates of 2,6-dimethylaniline derivatives, their use in treatment and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees